blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3423581

EP3423581 - TARGETING MICRORNA FOR CANCER TREATMENT [Right-click to bookmark this link]
StatusExamination is in progress
Status updated on  14.03.2024
Database last updated on 30.07.2024
FormerRequest for examination was made
Status updated on  07.12.2018
FormerThe international publication has been made
Status updated on  08.09.2017
Most recent event   Tooltip08.05.2024New entry: Additional fee for renewal fee: despatch of communication + time limit 
Applicant(s)For all designated states
Rhode Island Hospital
593 Eddy Street
Providence, RI 02903 / US
[2019/02]
Inventor(s)01 / TEREK, Richard
536 Wayland Avenue
Providence, RI 02906 / US
02 / CHEN, Qian
8 Tallwood Drive
Barrington, RI 02806 / US
03 / SUN, Xiaojuan
40 Wallis Avenue
Barrington, RI 02806 / US
 [2019/02]
Representative(s)Wilson Gunn
Blackfriars House The Parsonage
5th Floor
Manchester M3 2JA / GB
[N/P]
Former [2019/02]Lahrtz, Fritz
Isenbruck Bösl Hörschler LLP Patentanwälte Prinzregentenstrasse 68
81675 München / DE
Application number, filing date17760989.806.03.2017
[2019/02]
WO2017US20975
Priority number, dateUS201662304048P04.03.2016         Original published format: US 201662304048 P
[2019/02]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2017152182
Date:08.09.2017
Language:EN
[2017/36]
Type: A1 Application with search report 
No.:EP3423581
Date:09.01.2019
Language:EN
The application published by WIPO in one of the EPO official languages on 08.09.2017 takes the place of the publication of the European patent application.
[2019/02]
Search report(s)International search report - published on:US08.09.2017
(Supplementary) European search report - dispatched on:EP31.01.2020
ClassificationIPC:C12N15/113, C12N15/11, A61K31/7088, A61K31/713
[2019/47]
CPC:
C12N15/113 (EP,US); A61K31/7105 (EP,US); A61K31/395 (EP,US);
A61K45/06 (EP,US); A61K9/0019 (EP,US); A61K9/5184 (EP,US);
C12N2310/113 (EP,US) (-)
C-Set:
A61K31/395, A61K2300/00 (EP);
A61K31/7105, A61K2300/00 (EP)
Former IPC [2019/02]C12N15/113, C12N15/11
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/02]
TitleGerman:TARGETING VON MIKRORNA ZUR KREBSBEHANDLUNG[2019/02]
English:TARGETING MICRORNA FOR CANCER TREATMENT[2019/02]
French:CIBLAGE DE MICRO-ARN POUR LE TRAITEMENT DU CANCER[2019/02]
Entry into regional phase04.10.2018National basic fee paid 
04.10.2018Search fee paid 
04.10.2018Designation fee(s) paid 
04.10.2018Examination fee paid 
Examination proceduredeletedDate on which the examining division has become responsible
04.10.2018Examination requested  [2019/02]
28.08.2020Amendment by applicant (claims and/or description)
13.03.2024Despatch of a communication from the examining division (Time limit: M04)
Fees paidRenewal fee
28.03.2019Renewal fee patent year 03
12.03.2020Renewal fee patent year 04
12.03.2021Renewal fee patent year 05
14.01.2022Renewal fee patent year 06
12.01.2023Renewal fee patent year 07
Penalty fee
Additional fee for renewal fee
31.03.202408   M06   Not yet paid
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[I]  - JIANG DONG ET AL, "The overexpression of miR-30a affects cell proliferation of chondrosarcoma via targeting Runx2", TUMOR BIOLOGY, KARGER, BASEL, CH, vol. 37, no. 5, doi:10.1007/S13277-015-4454-3, ISSN 1010-4283, (20151123), pages 5933 - 5940, (20151123), XP036218922 [I] 1,7,10,11,13,15 * page 5937 - page 5939 *

DOI:   http://dx.doi.org/10.1007/s13277-015-4454-3
 [I]  - ABUDUNAIBI AILI ET AL, "MicroRNA-10b suppresses the migration and invasion of chondrosarcoma cells by targeting brain-derived neurotrophic factor", MOLECULAR MEDICINE REPORTS, GR, (20151105), vol. 13, no. 1, doi:10.3892/mmr.2015.4506, ISSN 1791-2997, pages 441 - 446, XP055619004 [I] 1,7,10,11,13,15 * abstract *

DOI:   http://dx.doi.org/10.3892/mmr.2015.4506
 [I]  - LIU GUAN-TING ET AL, "CCL5 promotes vascular endothelial growth factor expression and induces angiogenesis by down-regulating miR-199a in human chondrosarcoma cells", CANCER LETTERS, NEW YORK, NY, US, (20141113), vol. 357, no. 2, doi:10.1016/J.CANLET.2014.11.015, ISSN 0304-3835, pages 476 - 487, XP029186357 [I] 1,7,10,11,13,15 * page 484 - page 485 *

DOI:   http://dx.doi.org/10.1016/j.canlet.2014.11.015
 [I]  - ISABELLA W.Y. MAK ET AL, "The Epigenetic Regulation of SOX9 by miR-145 in Human Chondrosarcoma : The Epigenetic Regulation of SOX9 by miR-145 in Chondrosarcoma", JOURNAL OF CELLULAR BIOCHEMISTRY, (20141111), vol. 116, no. 1, doi:10.1002/jcb.24940, ISSN 0730-2312, pages 37 - 44, XP055619034 [I] 1,7,10,11,13,15 * pages 42,44 *

DOI:   http://dx.doi.org/10.1002/jcb.24940
International search[XY]US2011105583  (CLEARY MICHELE A [US], et al) [X] 1-3, 41-43 * abstract, para [0008], [0055], [0189], [0200], [0303] * [Y] 47, 48, 50/(47, 48);
 [Y]US2015258094  (CHEN QIAN [US], et al) [Y] 47-50* para [0005], [0454], [0488], [0490] *;
 [X]US2015344883  (BROWN DAVID [US], et al) [X] 37-38 * para [0035], [0046], [0050], [0316], [0336] *;
 [XY]  - SUN et al., "miR-181a Targets RGS16 to Promote Chondrosarcoma Growth , Angiogenesis, and Metastasis", Mol Cancer Res, (20150901), vol. 13, no. 9, pages 1347 - 1357, XP055413923 [X] 13-15, 44-46 * , abstract, pg 1348, col 2, para 2, Fig. 2A-2B * [Y] 47, 49, 50/(47, 49)

DOI:   http://dx.doi.org/10.1158/1541-7786.MCR-14-0697
 [X]  - YOSHITAKA et al., "Analysis of microRNAs expressions in chondrosarcoma", J. Orthop. Res., (20131200), vol. 31, no. 12, pages 1992 - 1998, XP055413928 [X] 39 * , abstract, pg 1997, col 1, para 2, Fig.3a *

DOI:   http://dx.doi.org/10.1002/jor.22457
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.